Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219798 | 0.94 | F10 (1.00) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL220661 | 0.89 | F10 (0.89) | F10MAPK1 | |
| SCHEMBL219792 | 0.85 | F10 (0.81) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL219921 | 0.84 | F10 (0.80) | F10SMN1; SMN2 | |
| SCHEMBL222420 | 0.83 | F10 (0.78) | F10SMN1; SMN2 | |
| SCHEMBL221386 | 0.81 | F10 (0.74) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL3873911 | 0.79 | F10 (0.72) | F10 | |
| SCHEMBL219591 | 0.79 | F10 (0.72) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL221783 | 0.78 | F10 (0.71) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL4592742 | 0.78 | F10 (0.70) | F10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |